вход по аккаунту



код для вставкиСкачать
The Prostate 32:74 (1997)
Response to Letter to the Editor
We agree with Dr. Alexander’s suggestion that the
integrity of synthetic peptides needs to be carefully
ascertained for in vitro immunization studies. The
synthetic peptide used in our recently published study
[1] was confirmed to be a 9-mer peptide by mass spectroscopy performed by the manufacturer (Research
Genetics, Birmingham, AL). The same peptide corresponding to residues 146–154 of prostate specific antigen (PSA146–154) has been synthesized on four subsequent occasions over a two year period. Each preparation has been confirmed by mass spectroscopy and
has mediated specific lysis by the original (CTL) line.
We are examining whether the PSA 146–154 peptide is
naturally processed and presented for CTL recognition by tumor cells that endogenously synthesize PSA
protein. It is interesting to note that Correale et. al.
recently reported that an HLA-A2-restricted CTL line
elicited with an overlapping peptide corresponding to
residues 141–150 of PSA specifically lyses cells of the
HLA-A2 phenotype that endogenously produce PSA
© 1997 Wiley-Liss, Inc.
protein [2]. The PSA 141–150 peptide shares the potential to form disulfide bridges via the side chain of
the cystine residue at position 149, yet appears to emulate a naturally processed epitope from PSA protein.
David J. Peace, MD
Loyola University Medical Center
Cardinal Bernardin Cancer Center
Division of Hematology/Oncology
2160 South First Avenue
Maywood, IL 60153
1. Xue BH, Zhang Y, Sosman JA, Peace DJ: Induction of human
cytotoxic T lymphocytes specific for prostate-specific antgen.
Prostate 1997; 30:73–78.
2. Correale P, Walmsley K, Nieroda C, Zaremba S, Zhu M, Schlom
J, Tsang KY: In vitro generation of human cytotoxic T lymphocytes specific for peptides derived from prostate-specific antigen. J Natl Cancer Institute 1997; 89:293–300.
Без категории
Размер файла
71 Кб
Пожаловаться на содержимое документа